Epsolay (microencapsulated benzoyl peroxide cream 5%) / Sol-Gel, Viatris - LARVOL DELTA

Experience With Topical Acne Treatment (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Nov 2025 ➔ Nov 2026 | Trial primary completion date: May 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Acne Vulgaris

A Comprehensive Study on Adverse Reactions of Benzoyl Peroxide (BPO) in Dermatological Aesthetics Utilizing the FAERS Database. (PubMed, J Cosmet Dermatol) - "BPO usage in dermatological aesthetics is associated with various adverse reactions, primarily affecting the skin. The introduction of EPSOLAY has not altered the adverse reaction profile significantly. However, the risk of BPO decomposing into the carcinogen benzene under certain conditions necessitates enhanced patient education, improved production processes, and continuous post-marketing surveillance to ensure drug safety."

Journal • Acne Vulgaris • Dermatology • Oncology • Pain • Pruritus

Experience With Topical Acne Treatment (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Wake Forest University Health Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Acne Vulgaris

Experience With Topical Acne Treatment (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: May 2025 ➔ Nov 2025 | Trial primary completion date: Dec 2024 ➔ May 2025

Adherence • Trial completion date • Trial primary completion date • Acne Vulgaris

Sentiment Analysis of EPSOLAY (Microencapsulated Benzoyl Peroxide 5%) on Reddit: Pre- and Post-FDA Approval. (PubMed, J Drugs Dermatol) - No abstract available

FDA event • Journal

Comparison table: Some topical drugs for rosacea. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dermatology • Rosacea

Drugs for rosacea. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dermatology • Rosacea

Experience With Topical Acne Treatment (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Sep 2024 ➔ Dec 2024

Adherence • Trial completion date • Acne Vulgaris

Experience With Topical Acne Treatment (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Jun 2024 ➔ Sep 2024 | Trial primary completion date: Feb 2024 ➔ May 2024

Adherence • Trial completion date • Trial primary completion date • Acne Vulgaris

Epsolay™ (Microencapsulated Benzoyl Peroxide 5%) Cream for the Topical Treatment of Rosacea. (PubMed, Skinmed) - "It is effective at decreasing, and for some patients clearing, the papules, pustules, and telangiectasias associated with rosacea. It is well-tolerated with minimal adverse effects and has demonstrated efficacy comparable to other topical agents that are used for the condition."

Journal • Dermatology • Rosacea

Experience With Topical Acne Treatment (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Initiation date: Mar 2023 ➔ Jun 2023

Adherence • Trial initiation date • Acne Vulgaris

Epsolay - a benzoyl peroxide cream for rosacea. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dermatology • Rosacea

Experience With Topical Acne Treatment (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences

New P1 trial • Acne Vulgaris

"$SLGL Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY® https://t.co/ZpIKtYr46L #fdaapproval" (@stock_titan)

FDA event

"$SLGL Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY® https://t.co/1TRtq9wg4w" (@stock_titan)

Review

Study on potential molecular mechanism of Mongolian medicine Bawei Sanxiang San in treatment of chronic heart failure based on network pharmacology and molecular docking (PubMed, Zhongguo Zhong Yao Za Zhi) - "After the potential common targets between Bawei Sanxiang San and CHF were disco-vered, the interaction network diagram of "compound-target-pathway" was constructed using Cytoscape...Additionally, molecular docking showed that the bioactive compounds had good binding activity with the protein receptors of key target genes. Bawei Sanxiang San might exert therapeutic effects on CHF by regulating cardiomyocytes, angiogenic and inflammation related targets and pathways in a multi-component, multi-target and multi-pathway manner."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Immunology • Inflammation • HIF1A

"Congratulations Vered! Well deserved." (@EnedaToska)

"$SLGL Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY® https://t.co/VFjj579Vv7" (@stock_titan)

Review

"Thank you so much Vered! So happy to be part of the team. @JHBreastGyn" (@EnedaToska)

"Thanks Vered!" (@tingbao2011)

"Wonderful!!! Congrats, Vered!" (@AshaniTW)

"10x is very atypical for a service business. Vered and team did very well on that one!" (@celltherapy)

Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay for the Treatment of Inflammatory Lesions of Rosacea (GlobeNewswire) - "Sol-Gel Technologies...announced that its New Drug Application (NDA) for Epsolay® (benzoyl peroxide), an investigational proprietary topical cream for the treatment of inflammatory lesions of rosacea, containing 5% encapsulated benzoyl peroxide, has been accepted for filing by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for Epsolay is April 26, 2021." "

NDA • PDUFA date • Dermatology • Rosacea

"$SLGL FDA Accepts NDA For Epsolay for the Treatment of Inflammatory Lesions of Rosacea. PDUFA 04/26/21" (@BioStocks)

NDA • PDUFA date • Dermatology • Rosacea

The FDA-approved drug Nelfinavir inhibits lytic cell-free, but not cell-associated non-lytic transmission of human adenovirus. (PubMed, Antimicrob Agents Chemother) - "Conspicuously, Nelfinavir unco-vered slow-growing round-shaped HAdV-C2 foci, independent of neutralizing antibodies in the medium, indicative of non-lytic cell-to-cell transmission. Our study demonstrates the repurposing potential of Nelfinavir with post-exposure efficacy against different HAdVs, and describes an alternative non-lytic cell-to-cell transmission mode of HAdV."

FDA event • Journal • Human Immunodeficiency Virus • Immunology • Infectious Disease • Respiratory Diseases